Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
-$3.24 today
- Market cap
- $3.71B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
Volume 2.75M
Average 3.67M
TNGX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Tango Therapeutics, Inc.NASDAQ: TNGX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $48.93M rose 58.8% year over year, ahead of the +14.3% change in trailing-twelve-month research & development. Sequentially, it rose 31.5% from the prior quarter. Over 3 fiscal years it compounded at +7.7% a year.
Context
- Research & development amounted to 211.9% of revenue in FY2025, down 130.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +58.8% holds above the trailing-twelve-month pace of +14.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 132.17M USD
- Year-over-year change
- -8.2%
- 4-year CAGR
- +14.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 132.17M | -8.2% |
| FY2024 | 2024-12-31 | 143.92M | +24.9% |
| FY2023 | 2023-12-31 | 115.2M | +8.8% |
| FY2022 | 2022-12-31 | 105.91M | +36.4% |
| FY2021 | 2021-12-31 | 77.64M | — |
Research & Development vs competitors
How TNGX compares with its peers on the latest reported figures
- TNGX's LTM Sep 2026 research & development of $152.48M is the 5th highest of the 11 companies compared; the peer median is $131.23M.
- Its year-over-year change of +14.3% is the 4th highest of 11, against a peer median of +0.5%.
- Over three fiscal years its annual growth of +7.7% compares with a peer median of +5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.29B | +68.1% | +57.0% | — | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Jun 2026 | $270.72M | -4.1% | +2.0% | 2615.7% | |
| LTM Sep 2026 | $152.48M | +14.3% | +7.7% | — | |
| LTM Sep 2026 | $133.6M | +39.6% | -6.2% | — | |
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $101.77M | -11.6% | -4.0% | 291.9% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $79.09M | -33.8% | +0.5% | 473.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
| Peer median (excluding TNGX) | $131.23M | +0.5% | +5.7% | 290.9% | |
Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.28M |
| Gross Profit | 37.04M | 24.86M | 36.53M | 42.07M | 60.1M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.3% |
| Research & Development | 77.64M | 105.91M | 115.2M | 143.92M | 132.17M |
| Selling, General & Admin | 17.6M | 30.03M | 35.5M | 43.75M | 41.51M |
| Operating Expenses | 95.23M | 135.93M | 150.7M | 187.66M | 171.39M |
| Depreciation & Amortization | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| EBITDA | (57.05M) | (106.51M) | (99.2M) | (127.6M) | (99.31M) |
| EBITDA Margin | -154.0% | -428.5% | -271.6% | -303.3% | -159.2% |
| Operating Income | (58.19M) | (111.07M) | (114.17M) | (145.6M) | (111.29M) |
| Operating Margin | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Interest Income | 495K | 1.46M | 6.62M | 7.89M | 5.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 247K | 2.95M | 12.56M | 15.5M | 9.7M |
| Income Before Tax | (57.94M) | (108.12M) | (101.61M) | (130.09M) | (101.59M) |
| Pre-Tax Margin | -156.4% | -434.9% | -278.2% | -309.2% | -162.8% |
| Income Tax Expense | 292K | 54K | 134K | 208K | 4K |
| Net Income | (58.24M) | (108.18M) | (101.74M) | (130.3M) | (101.59M) |
| Net Margin | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
| EPS (Basic) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| EPS (Diluted) | (0.94) | (1.23) | (1.08) | (1.19) | (0.87) |
| Weighted Avg Shares | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
| Weighted Avg Shares (Diluted) | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
Tango Therapeutics, Inc.
NASDAQ:TNGX
Intrinsic Alpha fair value
Locked
Current Price
$21.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.